



August 4, 2023

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer, President, and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Chief Strategy Officer
Toshiya Kitagawa
(TEL. 03-6214-3600)

Notice Concerning Finalized Issuance of Stock Acquisition Rights (Paid Stock Options)

GNI Group (the Group) hereby announces that the details of the stock options (stock acquisition rights) issued by the Board of Directors on July 20, 2023 and the Executive Officers on the same day, were finalized today as follows.

1	Name of Stock Acquisition Rights	50th Series of Stock Acquisition Rights
2	Number of Stock Acquisition Rights Offered	7,800
3	Type and number of shares to be issued upon exercise of Stock Acquisition Rights	Common stock 780,000 shares
4	Payment for Stock Acquisition Rights	The issue price per one Stock Acquisition Right shall be 42 yen
5	Amount of assets to be contributed upon exercise of Stock Acquisition Rights	121,600 yen per Stock Acquisition Right 1,216 yen per share
6	Amount to be paid into capital when shares are issued upon exercise of Stock Acquisition Rights	608.0 yen per share
7	Number of persons receiving Stock Acquisition Rights	Company Directors: 7 Company Employees: 4 Total: 11

[Reference]

(1) Date of resolution by the Executive Officers July 20, 2023

(2) Allotment date August 4, 2023

About GNI Group, Inc.:

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below.

<https://www.gnipharma.com/>